KYMR Kymera Therapeutics Forecast, Technical & Fundamental Analysis
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives... Show more
KYMR is expected to report earnings to rise 100.00% to -124 cents per share on October 29
Q3'26
Est.
$-1.24
Q2'26
Beat
by $0.10
Q1'26
Beat
by $0.17
Q4'25
Missed
by $0.18
Q3'25
Missed
by $0.18
The last earnings report on August 05 showed earnings per share of -62 cents, beating the estimate of -72 cents. With 440.83K shares outstanding, the current market capitalization sits at 9.90B.
A.I. Advisor
published General Information
General Information
a biotechnology company, which engages in curing untreatable diseases and focuses on discovering and developing novel small molecule therapeutics
A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with GPCR. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then GPCR could also see price increases.
KYMR sees MACD Histogram crosses below signal line
KYMR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 31, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for KYMR moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYMR as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
KYMR broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KYMR advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 180 cases where KYMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KYMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.557) is normal, around the industry mean (20.183). P/E Ratio (0.000) is within average values for comparable stocks, (27.671). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.520). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (105.263) is also within normal values, averaging (441.890).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
